We are live on ! Find out more
VIVO

Meridian Bioscience Inc

Delisted

VIVO was delisted on the 30th of January, 2023.

166 hedge funds and large institutions have $956M invested in Meridian Bioscience Inc in 2013 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 67 increasing their positions, 43 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

601% more call options, than puts

Call options by funds: $505K | Put options by funds: $72K

56% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 43

27% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 15

9% more capital invested

Capital invested by funds: $880M → $956M (+$76.4M)

2% more funds holding

Funds holding: 163166 (+3)

Holders
166
Holders Change
+3
Holders Change %
+1.84%
% of All Funds
5.38%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
67
Reduced
43
Closed
15
Calls
$505K
Puts
$72K
Net Calls
+$433K
Net Calls Change
+$24K
Name Holding Trade Value Shares
Change
Change in
Stake
BCM
1
Brown Capital Management
Maryland
$101M +$459K +19,663 +0.5%
Neuberger Berman Group
2
Neuberger Berman Group
New York
$97.2M -$2.19M -93,747 -2%
T. Rowe Price Associates
3
T. Rowe Price Associates
Maryland
$72.3M +$174K +7,470 +0.2%
Vanguard Group
4
Vanguard Group
Pennsylvania
$66.8M +$6.86M +293,903 +12%
BFA
5
BlackRock Fund Advisors
California
$52M +$5.2M +222,588 +11%
Bank of New York Mellon
6
Bank of New York Mellon
New York
$47.4M -$1.48M -63,531 -3%
CPCM
7
Clifton Park Capital Management
Delaware
$37.4M
BTW
8
Boston Trust Walden
Massachusetts
$30.7M -$529K -22,654 -2%
BIT
9
BlackRock Institutional Trust
California
$27.9M -$572K -24,491 -2%
Invesco
10
Invesco
Georgia
$26.2M +$1.44M +61,603 +6%
ACM
11
Atlanta Capital Management
Georgia
$26.1M +$299K +12,792 +1%
CCA
12
Conestoga Capital Advisors
Pennsylvania
$20.9M +$1.72M +73,450 +9%
State Street
13
State Street
Massachusetts
$19.8M +$287K +12,286 +1%
CI
14
Cincinnati Insurance
Ohio
$19.4M
CFC
15
Cincinnati Financial Corp
Ohio
$18.4M
Northern Trust
16
Northern Trust
Illinois
$18.1M -$215K -9,228 -1%
New York State Common Retirement Fund
17
New York State Common Retirement Fund
New York
$17.6M
Royal Bank of Canada
18
Royal Bank of Canada
Ontario, Canada
$16.5M +$1.95M +83,524 +14%
Schroder Investment Management Group
19
Schroder Investment Management Group
United Kingdom
$16.4M +$11.3M +482,000 +227%
BA
20
Broadview Advisors
Wisconsin
$13.4M
DRZID
21
DePrince Race & Zollo Inc (DRZ)
Florida
$11.8M -$16.6M -709,767 -59%
GKIM
22
GW&K Investment Management
Massachusetts
$9.98M +$699K +29,952 +8%
Ameriprise
23
Ameriprise
Minnesota
$8.86M -$1.99M -85,213 -19%
Dimensional Fund Advisors
24
Dimensional Fund Advisors
Texas
$6.87M +$3.1M +132,780 +84%
Norges Bank
25
Norges Bank
Norway
$6.39M +$952K +40,750 +18%

VIVO Hedge Fund Activity: Q3 2013 in Review

166 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q3 2013, worth a combined $956M — up 8.7% from $880M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new VIVO positions and 15 closed out — a net gain of 4 holders — while 67 added to existing stakes and 43 trimmed.

The largest buyer was Schroder Investment Management Group, adding an estimated $11.3M. The largest seller was DePrince Race & Zollo Inc (DRZ), cutting an estimated $16.6M.

  • 166 institutional investors held Meridian Bioscience Inc (VIVO) as of Q3 2013, up from 163 in Q2 2013.
  • Funds reported $956M of Meridian Bioscience Inc stock for Q3 2013, up 8.7% quarter-over-quarter.
  • 19 funds opened new Meridian Bioscience Inc positions in Q3 2013 and 15 closed out, a net change of +4 holders.
  • The largest Meridian Bioscience Inc buyer in Q3 2013 was Schroder Investment Management Group, an estimated $11.3M added.
  • The largest Meridian Bioscience Inc seller in Q3 2013 was DePrince Race & Zollo Inc (DRZ), an estimated $16.6M sold.

Based on aggregated 13F filings for Q3 2013.